Outcome of Board Meeting

L~ MANUFACTURER OF ‘”"i BULK DRUGS & (] ’ )’ IMPORTERS OF DRUGS & PHARMACEUTICALS LTD. SOLVENTS & CHEMICALS H.0: 203/4 SAHAKAR BHAVAN, 340/48 N.N STREET, MUMBAI-400009 ® : (022) 23455543 Email: corporate@aareydrugs.com REGD OFF. & FACTORY: E-34 MIDC, TARAPUR, BOISAR, DIST.-THANE ® (02525) 271049 Email: info@aareydrugs.com CIN:L99999MHI1990PLC056538 Date: 14" August, 2026 BSE Limited National Stock Exchange of India Limited The Manager, Exchange Plaza Corporate Service Department Bandra Kurla Complex, P.J. Towers, Dalal Street, Bandra (E), Mumbai40-0 001 Mumbai — 400051 Scrip Code: 524412 NSE Symbol: AAREYDRUGS Sub: Outcome of Board Meeting held on today i.e 14"August, 2026 Dear Sir/Madam, This is to inform you that a meeting of the board of directors of the company was held today i.e. on Friday, 14th August, 2026 at the registered office of the company, inter alia, to consider and take on record the Unaudited Financial Results (on standalone basis) of the company for the first quarter ended on 30th June, 2026, pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 and basis recommendation of the Audit Committee has, inter alia, approved the following. 1. The Board of Directors of the Company has considered and approved the Unaudited Financial Results for the quarter ended 30Mune, 2026 along with the Limited Review Report, MD/CFO certification. 2. Statement of Deviation or Variation in Utilization of Funds Raised through Convertible Warrants (Preferential Issue). *Company segment is single Kindly find attached herewith a copy of the Unaudited standalone financial results along with Limited Review Report of the company for the first quarter ended on 30th June, 2026 and Statement of Deviation or Variation. Further, please note that in terms of the SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window of the Company will be open after 48 hours after the announcement of the said results. The meeting was started at 05:00 p.m. and was concluded at 07:00 p.m Kindly take the same on record. Thanking you, Yours Faithfully, For AAREY DRUGS & PHARMACEUTICALS LIMITED Nimit R Ghatalia Director DIN: 07069841 MOTILAL & ASSOCIATES LLP INDIA I Fin nd ae np ce in ad le n Ret s uA lu td si t oo fr ’ ts h eR Cev oi me pw a nR yep o pr ut r so un an _ tt h te o Q tu ha er t Re er gl uy l aa tn id on Y 3e 3a r o ft o t hD ea Ste E BU In a (u Ld isi tt ie nd g Obligations & Disclosure Requirements) Regulations, 2015, as amended Review Report to, The Board of Directors Aarey Drugs and Pharmaceuticals Limited 30re Sbye so,g item Retl ene ger e ses tftt 1h3e 5e0y as amended (“the listing Regulations™). . T a A S t c ach e hc o pcc ee c m pt ro o p ri er u lC oo ud n i vo n na t a em dn i n dep 1c n c r3a e g e 3 n w yay S woi n’ it ft td tas h ht hn eh dtm o eah Rta e Cr ehCn d g oeora ur me m3 lg pc p4 ae o aa, a tm g c ninne ( c yoii In o n ’t en ut si d s n 3o t 3ni A A i Bs c S n oa otr g n , fe 3 rd s 4 t 2 dpp hm ) r0 o e e i1n “ nas 3 fLI ci s i inb u a sp Dtl s tr l iee ie re r a ns eimf gm cmeo te r gn oRnf e rt ei dp n .g n er e ua ae rd lnn Op a,c ad ua li t r la rr ipa yl e o rt a ni ri r d sn a eo e .c scn p wi pc o ip oTero l t nhptf e sh t eis i ent br dglh ie Sa ” e ll ti ie ad i tp vs t n yr at d e e na mo s t It ie c sw ne n r r dm n tui i te l b a on i e h et n s ad e a s I xii nu n pn s d bnd s r edt i u eeeh a e sie n nr d sn conclusion on the statement based on our review. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 - “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Registered Office : 2nd Floor, Senior Estate, 7/C Parsi Panchayat Road, Andheri (East), Mumbai - 400069 Branches : New Delhi | Bhopal | Prayagraj | Bhuj Motilal & Associates LLP is registered with limited liability having LLPIN : AAX - 3175 MOTILAL & ASSOCIATES LLP C&( CHARTERED ACCOUNTANTS (AMEMBER FIRM OF M AR C K S NETWORK) INDIA 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS’) specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For Motilal & Associates LLP (a member firm of M A R C K S Network) Chartered Accountants ICATFRN: 106584W/W 100751 Motilal Jain Partner ICAI MRN: 036811 Place: Mumbai Date: 14™ August, 2026 UDIN: 26036811GOVODO3820 MANUFATURERS OF BULK DRUGS & DEALERS OF CHEMICAL & SOLVENTS m $ arey DRUGS & PHARMACEUTICALS LTD. &35 GSommawiissoniCosesss HEAD OFFICE : 1227, HUBTOWN SOLARIS, N.S. PHADKE MARG, OPP. TELLI GALLI, ANDHERI - (E), MUMBAI - 400 068 INDIA, TEL. : (022) 62872900/2999 E-mail : info@aareydrugs.com REGD. OFFICE & FACTORY : E-34, M.LD.C., TARAPUR, BOISAR, DIST.: PALGHAR - 401 506 TEL.: (02525) 622165 E-mail : works@aareydrugs.com Web : www.aareydrugs.com AAREY DRUGS & PHARMACEUTICALS LTD CIN: L99999MH1990PLCOS6538 STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR QUARTER ENDED 30TH JUNE, 2026 (Rs. In Lakhs except EPS) Quarter ended Year Ended Particulars 30.06.2026 31.03.2026 30.06.2025 31.03.2026 (Unaudited) (Audited) (Unaudited) (Audited) Revenue from Operations 446255 18,947.24 10,22083 47,226.90 Other Incame 171.50 (42.94) 155.18 609.71 TOTAL INCOME 4634.05) 18,904.29 10,376.00 4783661 EXPENSES Cost of Materials Consuried 434776 17,929.60 9,306.79 4505629 Changes in Inventories of Finished g 2 and Stock in trade (132.35) 9.61 476.78 394.41 Employee Benefit Expe 16.34 28.97 13.84 75.90 General Adminisiraive expense 17.95 24.09 16.95 92.81 Selling and Distribution E 34.62 339.09 39.89 397.46 Finance Cost 167.44 178.47 103.76 500.18 Depreciation and Amortiza 85.02 84.64 48.83 285.30 Other Expenses 45.70 181.83 196.33 492.84 TOTAL EXPENSES 4,582.49 18,776.29 10,203.18 47,295.19 Profit Before Exceptional Ttems and Tax 51.56 128.01 17282 541.42 Exceptional ltems = - - = Profit/ (Loss) Before Tax 5156 12801 17282 541.42 Tax Expenses (50.81) 2774 35.69 144,66 2) Short/(excess) provision of earlier years . = - . b) Current Tax 30.00 51.76 35.00 159.25 ©) Deferred Tax (80.81) (24.03) 0.69 (14.59) Profit/ (Loss) for the period from continuing operations 102.37 100.27 137.13 396.76 Profiti{less) from discontinued operations - = = 2 Tax expense of discontinued operations - - - - Profit/(foss) from Discantinued operations (after tax) - E 5 E Profiti(ioss) for the period 102.37 10027 137.13 396.76 Other Comprehensive Income = s R Total Comprehensive Income for the year 10237 100,27 137.13 396.76 Earnings per equity share : (of Rs. 10/~ cach) (for the periodiyear): * a) Basic EPS (Rs.) 0.36 035 048 139 b) Diluted EPS (Rs.) 0.36 033 048 139 Number of Shares 28,454, 28,454,303 28,454,303 Percentage of Shareholding 1 a 100% Paid-up Equity Share Capital (FV of Rs. 10/- each) ( [Showing first 8,000 characters — download PDF for full document]